AGEN
Agenus Inc

12,606
Loading...
Loading...
News
all
press releases
Agenus (AGEN) Reports Q2 Loss, Beats Revenue Estimates
Agenus (AGEN) delivered earnings and revenue surprises of -28.21% and +2.68%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·28d ago
News Placeholder
More News
News Placeholder
Gilead Sciences (GILD) Tops Q2 Earnings and Revenue Estimates
Gilead (GILD) delivered earnings and revenue surprises of +3.08% and +1.95%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates
AnaptysBio (ANAB) delivered earnings and revenue surprises of +10.67% and +36.82%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Zacks.com featured highlights include QuantumScape, Civeo and Agenus
QuantumScape, Civeo, and Agenus show sharp earnings acceleration, signaling potential upside before Wall Street catches on.
Zacks·1mo ago
News Placeholder
QuantumScape & 2 Other Stocks to Buy for Earnings Acceleration
QS, CVEO, and AGEN show strong earnings acceleration this month - often a signal of stock price momentum ahead.
Zacks·1mo ago
News Placeholder
Is CVS Health (CVS) Stock Outpacing Its Medical Peers This Year?
Here is how CVS Health (CVS) and Agenus (AGEN) have performed compared to their sector so far this year.
Zacks·1mo ago
News Placeholder
VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales
Shares of Viking slide after Q2 loss widens to 58 cents per share on rising R&D and nil revenues, missing estimates by 14 cents.
Zacks·2mo ago
News Placeholder
AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies
AZN's anselamimab fails to meet key goals in late-stage AL amyloidosis trials despite signs of subgroup benefit.
Zacks·2mo ago
News Placeholder
MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights
Madrigal Pharmaceuticals stock jumps 11% after securing a new U.S. patent for Rezdiffra's dosing, reinforcing exclusivity through 2044.
Zacks·2mo ago
News Placeholder
AstraZeneca Meets All Key Goals in Phase III Hypertension Study
AZN hits all endpoints in phase III study for baxdrostat, a first-in-class treatment targeting hard-to-manage hypertension.
Zacks·2mo ago

Latest AGEN News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.